Axolabs is a prominent contract manufacturing organisation (CMO) and contract development and manufacturing organisation (CDMO) that specializes in the production of chemically modified oligonucleotides, conjugates, and other biologics. Established as a vital supplier to the pharmaceutical industry, Axolabs focuses on offering advanced solutions for cell and gene therapy, as well as oligonucleotide synthesis. The company provides a comprehensive range of services, including synthesis for lead identification and optimization, the production of active pharmaceutical ingredients, and support for GLP toxicology studies.

Services include:
- APIs (Active Pharmaceutical Ingredients)
- Analytical Services
- Synthesis of chemically modified oligonucleotides
- Conjugation strategies and chemistries
- Synthesis of drug substance for GLP Tox studies
- Reference material and drug substance-related impurity markers
- Lead identification and lead optimization

Axolabs is dedicated to delivering high-quality products and services tailored to the needs of its clients in the pharmaceutical sector. For further details, please visit axolabs.com.